SHR-A1201

• UNSPSC Description:

  SHR-A1201 is a HER2-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer[1].

• Target Antigen:

  Antibody-Drug Conjugates (ADCs); EGFR

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/shr-a1201.html

• Smiles:

  S[R][A1201]

• References & Citations:

  [1]Xianjing Li, et al. Development and validation of pharmacokinetics assays for a novel HER2-targeting antibody-drug conjugate (SHR-A1201): Application to its dose-escalation pharmacokinetic study. J Pharm Biomed Anal. 2024 Mar 15:240:115964.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported